NCT01480154 2026-04-13
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
26 trialsNCT04132505 2026-04-06
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03825289 2025-04-16
THREAD
University of Utah
Phase 1 Active not recruiting
NCT05083780 2025-04-16
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
Asan Medical Center
Phase 1 Active not recruiting
NCT04145297 2024-11-18
UTAH
University of Utah
Phase 1 Completed
NCT04873895 2024-04-26
TACE-Ax-HCQ
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT03215264 2023-11-09
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00813423 2023-08-02
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT01023737 2023-02-13
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Completed
NCT04316169 2022-12-23
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Phase 1 Withdrawn
NCT04163107 2022-03-18
MYELOMA-HCQ
Norwegian University of Science and Technology
Phase 1 Completed
NCT03015324 2022-01-25
Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors
University of Kentucky
Phase 1 Completed
NCT02232243 2021-06-28
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
University of Kentucky
Phase 1 Completed
NCT01266057 2021-03-04
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01897116 2020-05-29
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00568880 2020-02-07
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00909831 2019-04-16
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01687179 2018-10-11
SAIL
Brigham and Women's Hospital
Phase 1 Completed
NCT02631252 2018-02-23
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia
University of Pittsburgh
Phase 1 Terminated
NCT02414776 2017-09-27
ABC01
Western Regional Medical Center
Phase 1 Terminated
NCT01689987 2017-09-07
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 1 Completed
NCT01026844 2017-01-30
Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital
Phase 1 Terminated
NCT01144169 2016-10-26
Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma
University of Pittsburgh
Phase 1 Terminated
NCT01634893 2016-03-25
Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Completed
NCT00714181 2016-02-18
Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01417403 2015-02-03
Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases
Virginia Commonwealth University
Phase 1 Terminated